Metalloproteinases (3.4.24) (e.g., Collagenase, Snake Venom Zinc Proteinase, Etc.) Patents (Class 424/94.67)
  • Patent number: 10369190
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 6, 2019
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Patent number: 10131703
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: November 20, 2018
    Assignee: INMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10119131
    Abstract: The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum. The method utilizes an improved medium for the cultivation of Clostridium histolyticum which includes a non-meat-derived (i.e., non-mammalian) peptone or vegetable peptone. The method includes one or more of: (1) reducing glucose content in the meat-free or vegetable-derived media; and (2) increasing the salt concentration in the meat-free or vegetable-derived media. Also provided is a drug product which includes collagenase I and collagenase II at an optimized fixed mass ratio, and which has a purity of greater than at least 95%.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: November 6, 2018
    Assignee: BIOSPECIFICS TECHNOLOGIES CORP.
    Inventors: Thomas L. Wegman, Bo Yu
  • Patent number: 10117892
    Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 6, 2018
    Assignee: Allergan, Inc.
    Inventors: Tracy Ann Perry, Rui Avelar, Justin Schwab, Zachary Dominguez, Edwin Kayda
  • Patent number: 10111938
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 30, 2018
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Patent number: 10039770
    Abstract: A method of treating atrophic cutaneous scarring in humans is claimed. The method involves the topical application of a therapeutic amount of prostaglandin F2-alpha (PGF 2?) or a PGF 2? analog directly to the area of atrophic scarring.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 7, 2018
    Assignee: Galderma S.A.
    Inventor: Warren J. Scherer
  • Patent number: 10022270
    Abstract: Methods and systems for performing laser-assisted surgery on an eye form a layer of bubbles in the Berger's space of the eye to increase separation between the posterior portion of the lens capsule of the eye and the anterior hyaloid surface of the eye. A laser is used to form the layer of bubbles in the Berger's space. The increased separation between the posterior portion of the lens capsule and the anterior hyaloid surface can be used to facilitate subsequent incision of the posterior portion of the lens capsule with decreased risk of compromising the anterior hyaloid surface. For example, the layer of bubbles can be formed prior to performing a capsulotomy on the posterior portion of the lens capsule.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: July 17, 2018
    Assignee: OPTIMEDICA CORPORATION
    Inventors: Georg Schuele, Julian Stevens, Dan E. Andersen
  • Patent number: 9808515
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: November 7, 2017
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Patent number: 9737570
    Abstract: The present invention provides a method of inducing hair follicle neogenesis in the skin of a subject in need by transplanting the mixture of the skin extract or the composition with epidermal cells or fibroblasts into the subject. The skin extract of the present invention is obtained by mincing and mixing a skin tissue with phosphate buffer solution, thawing the skin tissue after freeze. The composition of the present invention includes at least lumican, galectin-1 and apolipoprotein A-I.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: August 22, 2017
    Assignees: National Taiwan University, Academia Sinica
    Inventors: Sung-Jan Lin, Mai-Yi Fan, Yu-Ju Chen, Chia-Feng Tsai
  • Patent number: 9603910
    Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 28, 2017
    Assignee: FIDIA FARMACEUTICI S.p.A.
    Inventors: Susanna Vaccaro, Giovanni Gennari, Lanfranco Callegaro, Antonio Giannelli, Salvatore Caruso
  • Patent number: 9408864
    Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: August 9, 2016
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Akihiro Yoneda, Hirotoshi Ishiwatari
  • Patent number: 9254314
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: February 9, 2016
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Publication number: 20150147313
    Abstract: The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 28, 2015
    Inventors: Marcos Castanheira Alegria, Lucidio Cristoväo Fardelone, Marina Baiochi Riboldi Delalana, Josef Ernst Thiemann, Spartaco Astolfi Filho, Roberto Carlos Debom Moreira, Ogari de Castro Pacheco
  • Publication number: 20150132281
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 14, 2015
    Inventors: Irit Sagi, Eitan Wong, Ran Afik
  • Publication number: 20150132283
    Abstract: The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 14, 2015
    Inventor: Gary E. Borodic
  • Publication number: 20150132282
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 14, 2015
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Publication number: 20150104439
    Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventors: Josee Roy, Susan J. Drapeau, Jeffrey C. Marx
  • Publication number: 20150093373
    Abstract: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 2, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Edward C. DEMPSEY
  • Publication number: 20150093372
    Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Applicant: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Mayland Chang, Shahriar Mobashery, Mijoon Lee
  • Publication number: 20150086531
    Abstract: Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein.
    Type: Application
    Filed: September 24, 2013
    Publication date: March 26, 2015
    Applicant: Allergan, Inc.
    Inventors: Guang-Liang Jiang, Catherine Turkel
  • Publication number: 20150086533
    Abstract: A method of treating anxiety disorder comprising the steps of: identifying a subject with one or more symptoms of an anxiety disorder; a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of anxiety disorder.
    Type: Application
    Filed: November 28, 2014
    Publication date: March 26, 2015
    Inventor: Gary E. Borodic
  • Publication number: 20150086532
    Abstract: A method of treating major depression comprising the steps of: identifying a subject with one or more symptoms of a depressive disorder; and administering a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of depression.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 26, 2015
    Inventor: Gary E. Borodic
  • Publication number: 20150079069
    Abstract: Methods for modification of mechanical properties or a shape of a mammalian tissue, excluding scar, blood clot, fat; including a step of contacting the tissue with an isolated eukaryotic endopeptidase in an amount sufficient to cause a modification of mechanical properties of the tissue or its shape, but insufficient to cause degradation of the tissue's into incohesive parts, and to the use of eukaryotic endopeptidases for use in methods for treatment of the mammalian body.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 19, 2015
    Applicant: ELASTOMICS AB
    Inventor: Aleksei Rozkov
  • Publication number: 20150071879
    Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).
    Type: Application
    Filed: October 17, 2014
    Publication date: March 12, 2015
    Inventor: Jan JEZEK
  • Publication number: 20150064166
    Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.
    Type: Application
    Filed: November 5, 2014
    Publication date: March 5, 2015
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
  • Publication number: 20150064167
    Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Inventors: Ivan Aguilar, Gustavo M. Gaxiola, Gilberto P. Paz
  • Publication number: 20150060462
    Abstract: A portable neurotoxin injection tray apparatus that includes a vial section with multiple compartments. Each compartment is capable of storing at least one neurotoxin vial or at least one saline vial. The apparatus also includes a dosage compartment with a tilted support member for positioning at least one of the neurotoxin vials in a tilted orientation. Further, the apparatus includes an injection syringe section that includes multiple compartments, where each compartment is designated to store at least one injection syringe filled with a different dosage of neurotoxin.
    Type: Application
    Filed: September 4, 2014
    Publication date: March 5, 2015
    Inventors: Rand Colbert, Russell G. Olsen
  • Publication number: 20150064165
    Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Tracy Ann Perry, Rui Avelar, Justin Schwab, Zackary Dominguez, Edwin Kayda
  • Publication number: 20150064163
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.
    Type: Application
    Filed: September 2, 2012
    Publication date: March 5, 2015
    Applicant: LIFENET HEALTH
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
  • Publication number: 20150056179
    Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.
    Type: Application
    Filed: April 17, 2013
    Publication date: February 26, 2015
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Susanna Vaccaro, Michele Caputo, Christian Cuppari, Giovanni Gennari
  • Publication number: 20150044171
    Abstract: Compositions and methods for the treatment of thrombotic thrombocytopenic purpura are disclosed.
    Type: Application
    Filed: June 23, 2014
    Publication date: February 12, 2015
    Inventor: X. Long Zheng
  • Publication number: 20150037402
    Abstract: Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within into the gastrointestinal (GI) tract in need of treatment. Preferably, the formulation is applied via a roller, sponge or nozzle that is attached to an endoscope.
    Type: Application
    Filed: February 4, 2013
    Publication date: February 5, 2015
    Inventors: Michael B. Chancellor, Jonathan H. Kaufman
  • Publication number: 20150030583
    Abstract: The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 29, 2015
    Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Malcolm A.S. Moore, Server A. Ertem
  • Publication number: 20150030584
    Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 29, 2015
    Applicant: SYNTAXIN LIMITED
    Inventor: Andreas Rummel
  • Publication number: 20150010533
    Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 8, 2015
    Inventor: Eric R. First
  • Publication number: 20150010532
    Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 8, 2015
    Inventor: Wayne K. Herber
  • Publication number: 20150004153
    Abstract: A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Applicant: HOMS, LLC
    Inventor: Allen Jones
  • Patent number: 8920795
    Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 30, 2014
    Assignee: Medy-Tox Inc.
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek
  • Publication number: 20140377249
    Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Susanna VACCARO, Giovanni GENNARI, Lanfranco CALLEGARO, Antonio GIANNELLI, Salvatore CARUSO
  • Publication number: 20140377319
    Abstract: Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid.
    Type: Application
    Filed: April 18, 2012
    Publication date: December 25, 2014
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Eric C. Leuthardt, Daniel W. Moran, David Holtzman, Philip Bayly, David Brody, Ralph G. Dacey, Sam Fok, David Jeremiah Garrison, Guy M. Genin, Eriks Lusis, Rohit Pappu, Jingwei Xie, Greg Zipfel
  • Publication number: 20140377248
    Abstract: This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor Xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use. The invention further relates to novel di-chain clostridial neurotoxins and nucleic acid sequences encoding such novel di-chain clostridial neurotoxins.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Inventors: Swen Grein, Kerstin Hoelscher, Annett Eylenstein
  • Patent number: 8916150
    Abstract: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: December 23, 2014
    Assignee: CNSS IP Holdings, Inc.
    Inventor: Charles N. S. Soparkar
  • Publication number: 20140356344
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Applicant: BioAtla LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 8900576
    Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: December 2, 2014
    Assignee: Fidia Farmaceutici S.p.A
    Inventors: Susanna Vaccaro, Giovanni Gennari, Lanfranco Callegaro, Antonio Giannelli, Salvatore Caruso
  • Publication number: 20140348828
    Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.
    Type: Application
    Filed: August 14, 2014
    Publication date: November 27, 2014
    Inventors: Keith Alan FOSTER, John Andrew CHADDOCK, Conrad Padraig QUINN, John Robert PURKISS
  • Publication number: 20140341879
    Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof wherein the peptide is D-Arg-26-Dmt-Lys-Phe-NH2 (SS-31).
    Type: Application
    Filed: January 7, 2014
    Publication date: November 20, 2014
    Applicant: Stealth Peptides International, Inc.
    Inventors: Kenneth Borow, D. Travis Wilson
  • Publication number: 20140341801
    Abstract: Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit.
    Type: Application
    Filed: July 30, 2014
    Publication date: November 20, 2014
    Inventors: Michael D. LAUFER, David C. AUTH, Christopher J. DANEK, William WIZEMAN, Gary KAPLAN
  • Publication number: 20140341882
    Abstract: The present invention provides a therapeutic agent for Alzheimer's disease. The therapeutic agent contains membrane vesicles (exosomes) of adipose tissue-derived mesenchymal stem cells, and the membrane vesicles (exosomes) contain neprilysin. Through the research by the inventors of the present invention, it was revealed that exosomes secreted by human adipose tissue-derived mesenchymal stem cells contain neprilysin, which degrades amyloid-? as a pathogenic protein of Alzheimer's disease. When exosomes secreted by human adipose tissue-derived mesenchymal stem cells were administered to the brains of Alzheimer's disease model mice, the generation of amyloid-? was inhibited.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 20, 2014
    Inventor: Takahiro Ochiya
  • Publication number: 20140335072
    Abstract: The present invention is directed to a method of treating or reducing EFP in a patient comprising administering one or multiple low dose injections of collagenase to an area affected by EFP. The invention encompasses methods wherein the dose of collagenase per injection is between about 50 to about 200 ABC units and/or wherein the concentration of collagenase is between about 50 to about 2000 ABC units/milliliter (ml).
    Type: Application
    Filed: April 17, 2014
    Publication date: November 13, 2014
    Applicant: Auxilium Pharmaceuticals, Inc.
    Inventor: Susan G. Emeigh Hart
  • Publication number: 20140335146
    Abstract: Provided is a growth factor anchoring type bone graft material, wherein a bone graft substrate exposing at least a collagen fiber is bound to a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide. The same can be produced by mixing a bone graft substrate and a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide, and is also superior in osteogenic ability.
    Type: Application
    Filed: March 26, 2012
    Publication date: November 13, 2014
    Applicants: NATIONAL UNIVERSITY CORPORATION KAGAWA, SCHOOL JURIDICAL PERSON KITASATO INSTITUTE
    Inventors: Kentaro Uchida, Koji Naruse, Masashi Takaso, Takehiko Mima, Osamu Matsushita, Takashi Haraguchi, Nozomu Nishi